Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),

Aziz Nazha, Elias Jabbour, Jorge E. Cortes, Susan O'Brien, MD, Jenny Shan, PhD, Guillermo Garcia-Manero, Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 3769.

https://doi.org/10.1182/blood.V118.21.3769.3769

Published: 2011

Journal Articles

Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience

Hun Lee, MD, Jorge E. Cortes, Susan O'Brien, MD, Elias Jabbour, Guillermo Garcia-Manero, Alfonso Quintas-Cardama, MD, Jenny Shan, PhD, Mary Beth Rios, RN, Farhad Ravandi, MD, Stefan Faderl, MD, Tapan Kadia, Gautam Borthakur, Xuelin Huang, PhD, Hagop M. Kantarjian

Blood (2011) 118 (21): 2750.

https://doi.org/10.1182/blood.V118.21.2750.2750

Published: 2011

Journal Articles

Dynamic Prognostic Model to Identify Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Mf) At the Highest Risk of Death and Transformation to Acute Myeloid Leukemia

Alfonso Quintás-Cardama, MD, Jenny Shan, PhD, Sherry Pierce, RN, BS, Hagop M. Kantarjian, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 2821.

https://doi.org/10.1182/blood.V118.21.2821.2821

Published: 2011

Journal Articles

The Achievement of An Early Complete Cytogenetic Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs).

Elias Jabbour, MD, Hagop M. Kantarjian, MD, Jenny Shan, PhD, Susan O'Brien, MD, Tapan Kadia, MD, Gautam Borthakur, MD, Alfonso Quintas-Cardama, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Jorge Cortes, MD

Blood (2010) 116 (21): 3429.

https://doi.org/10.1182/blood.V116.21.3429.3429

Published: 2010

Journal Articles

Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).

Alireza Eghtedar, MD, Stefan Faderl, MD, Hagop Kantarjian, MD, Susan O'Brien, MD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, MD, Tapan Kadia, MD, Sherry A. Pierce, RN, BS, Jenny Shan, PhD, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2010) 116 (21): 1085.

https://doi.org/10.1182/blood.V116.21.1085.1085

Published: 2010

Journal Articles

The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2 nd ) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS)

Elias Jabbour, MD, Hagop M. Kantarjian, MD, Jenny Shan, PhD, Susan O'Brien, MD, Alfonso Quintas-Cardama, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD

Blood (2010) 116 (21): 2289.

https://doi.org/10.1182/blood.V116.21.2289.2289

Published: 2010

Journal Articles

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

Elias Jabbour, MD, Hagop Kantarjian, MD, Susan O'Brien, MD, Jenny Shan, PhD, Guillermo Garcia-Manero, MD, William Wierda, MD, PhD, Farhad Ravandi, MD, Gautam Borthakur, MD, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2009) 114 (22): 509.

https://doi.org/10.1182/blood.V114.22.509.509

Published: 2009

Journal Articles

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

Dushyant Verma, MD, FACP, Hagop M Kantarjian, MD, Jenny Shan, PhD, Susan O'Brien, MD, Amit Verma, MD, Elias Jabbour, MD, Srdan Verstovsek, MD, PhD, Tapan Kadia, MD, Mary Beth Rios, RN, Jorge Cortes, MD

Blood (2009) 114 (22): 505.

https://doi.org/10.1182/blood.V114.22.505.505

Published: 2009

Journal Articles

Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy

Farhad Ravandi, MBBS, Jean-Pierre Issa, MD, Guillermo Garcia-Manero, MD, Susan O’Brien, MD, Sherry Pierce, BSN, Jenny Shan, PhD, Srdan Verstovsek, MD, PhD, Stefan Faderl, MD, Jorge Cortes, MD, Hagop Kantarjian, MD

Blood (2008) 112 (11): 2955.

https://doi.org/10.1182/blood.V112.11.2955.2955

Published: 2008

Journal Articles

The Time to Cytogenetic Response Determines Survival in CML Patients (Pts) Receiving Second-Line Tyrosine Kinase Inhibitors, and Allows Early Identification of Pts Destined To Fail Therapy.

Constantine S. Tam, MBBS, Hagop Kantarjian, MD, Gautam Borthakur, MD, William Wierda, MD PhD, Farhad Ravandi, MD, Susan O’Brien, MD, Jenny Shan, PhD, Jorge Cortes, MD

Blood (2007) 110 (11): 1931.

https://doi.org/10.1182/blood.V110.11.1931.1931

Published: 2007

Journal Articles

The Clinical Significance of Biphenotypia in Blastic Phase CML.

Constantine S. Tam, MBBS, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, William G. Wierda, MD PhD, Jenny Shan, PhD, Joselle Otero-Palacios, BSc, Ahmed Awais, MD, Farhad Ravandi-Kashani, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 4785.

https://doi.org/10.1182/blood.V108.11.4785.4785

Published: 2006

Journal Articles

Sokal and Hasford Scores Are Able To Predict Cytogenetic Response and Survival in CML Patients Who Failed Prior Therapy and Are Receiving Salvage Therapy with Imatinib or Other Tyrosine Kinase Inhibitors.

Constantine S. Tam, MBBS, Hagop M. Kantarjian, MD, Jenny Shan, PhD, William G. Wierda, MD, PhD, Alessandra Ferrajoli, MD, Charles Asa Koller, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 2157.

https://doi.org/10.1182/blood.V108.11.2157.2157

Published: 2006

NARROW

EUTOS Score Is Not Predictive for Survival and Outcome in Patients (pts) with Chronic Myeloid Leukemia in Early Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKIs) At MD Anderson Cancer Center (MDACC),

Improved Survival in Chronic Myeloid Leukemia (CML) Since the Introductin of Imatinib Therapy - A Single Institution Historical Experience

Dynamic Prognostic Model to Identify Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (Mf) At the Highest Risk of Death and Transformation to Acute Myeloid Leukemia

The Achievement of An Early Complete Cytogenetic Response (CCyR) Is A Major Determinant for Outcome In Patients (pts) with Early Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs).

Incidence of Secondary Neoplasms In Patients with Acute Promyelocytic Leukemia Treated with All-Trans-Retinoic Acid (ATRA) with Chemotherapy or with Arsenic Trioxide (ATO).

The Achievement of a 3-Month Complete Cytogenetic Response (3-mo CCyR) to Second Generation (2 nd ) Tyrosine Kinase Inhibitors (TKI) Post Imatinib Failure Is the Only Predictive Factor for Event-Free (EFS) and Overall Survival (OS)

Predictive Factors for Response and Outcome in Patients (pts) Treated with Second Generation Tyrosine Kinase Inhibitors (2-TKI) for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Post Imatinib Failure.

Sustained Complete Molecular Response to Imatinib in Chronic Myeloid Leukemia (CML): a Target Worth Aiming and Achieving?.

Hypomethylating Therapy in Patients with AML and High-Risk MDS and Chromosome 5 and 7 Abnormalities Is Associated with An Improved Outcome Compared to Conventional Chemotherapy

The Time to Cytogenetic Response Determines Survival in CML Patients (Pts) Receiving Second-Line Tyrosine Kinase Inhibitors, and Allows Early Identification of Pts Destined To Fail Therapy.

The Clinical Significance of Biphenotypia in Blastic Phase CML.

Sokal and Hasford Scores Are Able To Predict Cytogenetic Response and Survival in CML Patients Who Failed Prior Therapy and Are Receiving Salvage Therapy with Imatinib or Other Tyrosine Kinase Inhibitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only